Boehringer Ingelheim Strengthens Fibrosis Portfolio With JASCAYD
Ingelheim, Germany – May 22, 2026 Boehringer Ingelheim announced that the European Medicines Agency’s Committee for Medicinal Products for...
artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology NSCLC Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
Ingelheim, Germany – May 22, 2026 Boehringer Ingelheim announced that the European Medicines Agency’s Committee for Medicinal Products for...
SAN DIEGO, May 11, 2026 aTyr Pharma announced a major regulatory and clinical development update for its lead investigational...
